|
|
|
|
| LEADER |
01000naa a22002652 4500 |
| 001 |
NLM299855708 |
| 003 |
DE-627 |
| 005 |
20231225101243.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231225s2019 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1016/j.clim.2019.07.011
|2 doi
|
| 028 |
5 |
2 |
|a pubmed24n0999.xml
|
| 035 |
|
|
|a (DE-627)NLM299855708
|
| 035 |
|
|
|a (NLM)31374257
|
| 035 |
|
|
|a (PII)S1521-6616(19)30045-2
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Yan, Xiaoming
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Unbalanced expression of membrane-bound and soluble inducible costimulator and programmed cell death 1 in patients with myasthenia gravis
|
| 264 |
|
1 |
|c 2019
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 18.05.2020
|
| 500 |
|
|
|a Date Revised 18.05.2020
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a Copyright © 2019 Elsevier Inc. All rights reserved.
|
| 520 |
|
|
|a This study aimed to investigate the possible functions and mechanisms of positive and negative costimulatory molecules in the pathological process of myasthenia gravis (MG). The expression levels of membrane-bound inducible costimulator (ICOS) and programmed cell death 1 (PD-1) in peripheral blood T cells, their corresponding ligands ICOSL and PDL-1 on B cells, and their soluble forms (sICOS, sPD-1, sICOSL, and sPDL-1) in plasma were detected in patients with untreated-stage MG (USMG) and remission-stage MG (RSMG). The results showed that the expression levels of membrane-bound ICOS and PD-1 in the peripheral blood T cells of the USMG group and their corresponding ligands ICOSL and PD-L1 on B cells were significantly increased compared to those in the RSMG group and healthy controls (HCs). The levels of sICOSL and sPD-1 were significantly upregulated in USMG patients compared to those in the RSMG and HC groups, while the levels of sICOS and sPD-L1 were not different. The expression of PD-L1 on CD19+ B cells was positively correlated with the concentrations of AchR Ab in the USMG group. The expression of ICOS and PD-1 in CD4+ T cells and the expression of ICOSL and PD-L1 on CD19+ B cells were positively correlated with the quantitative myasthenia gravis (QMG) scores in the USMG group. Also, in the USMG group, the plasma levels of sICOSL and sPD-1 were positively correlated with the QMG scores. In addition, the percentage of peripheral blood follicular helper T (Tfh) cells in the USMG group was positively correlated with ICOS and PD-1 expression on CD4+ T cells and ICOSL and PD-L1 expression on CD19+ B cells. There were positive correlations between sICOSL and sPD-1 levels and the percentage of peripheral blood Tfh cells and plasma interleukin-21 (IL-21) levels in the USMG group. The results suggest that the positive ICOS/ICOSL and negative PD-1/PD-L1 costimulatory molecule pairs participate in the pathological process of MG. Abnormal sICOSL and sPD-1 expression might interfere with the normal signal transduction of ICOS and PD-1 on Tfh cells, causing excessive activation of Tfh cells and promotion of disease progression. sICOSL and sPD-1 have potential value in monitoring MG disease states
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Research Support, Non-U.S. Gov't
|
| 650 |
|
4 |
|a Follicular helper T cell
|
| 650 |
|
4 |
|a Inducible costimulatory molecule
|
| 650 |
|
4 |
|a Myasthenia gravis
|
| 650 |
|
4 |
|a Programmed cell death 1
|
| 650 |
|
4 |
|a sICOSL
|
| 650 |
|
4 |
|a sPD-1
|
| 650 |
|
7 |
|a B7-H1 Antigen
|2 NLM
|
| 650 |
|
7 |
|a CD274 protein, human
|2 NLM
|
| 650 |
|
7 |
|a ICOSLG protein, human
|2 NLM
|
| 650 |
|
7 |
|a Inducible T-Cell Co-Stimulator Ligand
|2 NLM
|
| 650 |
|
7 |
|a Inducible T-Cell Co-Stimulator Protein
|2 NLM
|
| 650 |
|
7 |
|a Ligands
|2 NLM
|
| 650 |
|
7 |
|a PDCD1 protein, human
|2 NLM
|
| 650 |
|
7 |
|a Programmed Cell Death 1 Receptor
|2 NLM
|
| 700 |
1 |
|
|a Gu, Yanzheng
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Wang, Caiqin
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Sun, Simao
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Wang, Xiaozhu
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Tian, Jingluan
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Wang, Mingyuan
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Ji, Xiaopei
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Duan, Xiaoyu
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Gao, Hanqing
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Fang, Qi
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Dong, Wanli
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Zhang, Xueguang
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Xue, Qun
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 207(2019) vom: 01. Okt., Seite 68-78
|w (DE-627)NLM098196855
|x 1521-7035
|7 nnns
|
| 773 |
1 |
8 |
|g volume:207
|g year:2019
|g day:01
|g month:10
|g pages:68-78
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1016/j.clim.2019.07.011
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 207
|j 2019
|b 01
|c 10
|h 68-78
|